Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents

Shohei Mizuno, Koji Kawamura, Ichiro Hanamura, Kazutaka Sunami, Takehiko Mori, Fumihiko Nakamura, Shinsuke Iida, Hideyuki Nakazawa, Masanori Makita, Shinichi Kako, Masashi Sawa, Yasunori Ueda, Hiroyuki Takahashi, Yoshinobu Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Hiroyuki Takamatsu, Akiyoshi Takami

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Clinical trials evaluating the role of autologous hematopoietic stem cell transplantation (auto-HCT) in multiple myeloma have mostly included patients aged <65 years. Therefore, this study was aimed to evaluate the efficacy and safety of auto-HCT in elderly patients with multiple myeloma in the era of novel agents. We retrospectively analyzed 2056 patients with multiple myeloma, who underwent auto-HCT in 2007–2014 (287 were aged ≥65 years). We evaluated the 100-day treatment-related mortality (TRM) and overall survival (OS) in two groups; elderly patients (≥65 years) who underwent auto-HCT compared with younger patients (<65 years). In the propensity score–matched-pair analysis used to adjust for possible selection bias, the incidence of 100-day TRM between patients aged <65 (0.4%; 95% confidence interval [CI]: 0.0–2.0%) and ≥65 years (1.2%; 95% CI: 0.3–3.1%) showed no statistically significant difference (p = 0.31). The probability of the 5-year OS after transplantation in those aged <65 (62.5%; 95% CI: 58.6–66.1%) and ≥65 (63.5%; 95% CI: 52.2–72.7%) years was also not significantly different (p = 0.56). This study showed that the safety and efficacy of auto-HCT in elderly patients with multiple myeloma in the era of novel agents compared with younger patients were similar.

Original languageEnglish
JournalBone Marrow Transplantation
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Hematopoietic Stem Cell Transplantation
Safety
Confidence Intervals
Survival
Mortality
Selection Bias
Transplantation
Clinical Trials
Incidence
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents. / Mizuno, Shohei; Kawamura, Koji; Hanamura, Ichiro; Sunami, Kazutaka; Mori, Takehiko; Nakamura, Fumihiko; Iida, Shinsuke; Nakazawa, Hideyuki; Makita, Masanori; Kako, Shinichi; Sawa, Masashi; Ueda, Yasunori; Takahashi, Hiroyuki; Kanda, Yoshinobu; Ichinohe, Tatsuo; Atsuta, Yoshiko; Takamatsu, Hiroyuki; Takami, Akiyoshi.

In: Bone Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Mizuno, S, Kawamura, K, Hanamura, I, Sunami, K, Mori, T, Nakamura, F, Iida, S, Nakazawa, H, Makita, M, Kako, S, Sawa, M, Ueda, Y, Takahashi, H, Kanda, Y, Ichinohe, T, Atsuta, Y, Takamatsu, H & Takami, A 2019, 'Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents', Bone Marrow Transplantation. https://doi.org/10.1038/s41409-019-0478-4
Mizuno, Shohei ; Kawamura, Koji ; Hanamura, Ichiro ; Sunami, Kazutaka ; Mori, Takehiko ; Nakamura, Fumihiko ; Iida, Shinsuke ; Nakazawa, Hideyuki ; Makita, Masanori ; Kako, Shinichi ; Sawa, Masashi ; Ueda, Yasunori ; Takahashi, Hiroyuki ; Kanda, Yoshinobu ; Ichinohe, Tatsuo ; Atsuta, Yoshiko ; Takamatsu, Hiroyuki ; Takami, Akiyoshi. / Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents. In: Bone Marrow Transplantation. 2019.
@article{d44288a1b83f4e6884415d85877c35f3,
title = "Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents",
abstract = "Clinical trials evaluating the role of autologous hematopoietic stem cell transplantation (auto-HCT) in multiple myeloma have mostly included patients aged <65 years. Therefore, this study was aimed to evaluate the efficacy and safety of auto-HCT in elderly patients with multiple myeloma in the era of novel agents. We retrospectively analyzed 2056 patients with multiple myeloma, who underwent auto-HCT in 2007–2014 (287 were aged ≥65 years). We evaluated the 100-day treatment-related mortality (TRM) and overall survival (OS) in two groups; elderly patients (≥65 years) who underwent auto-HCT compared with younger patients (<65 years). In the propensity score–matched-pair analysis used to adjust for possible selection bias, the incidence of 100-day TRM between patients aged <65 (0.4{\%}; 95{\%} confidence interval [CI]: 0.0–2.0{\%}) and ≥65 years (1.2{\%}; 95{\%} CI: 0.3–3.1{\%}) showed no statistically significant difference (p = 0.31). The probability of the 5-year OS after transplantation in those aged <65 (62.5{\%}; 95{\%} CI: 58.6–66.1{\%}) and ≥65 (63.5{\%}; 95{\%} CI: 52.2–72.7{\%}) years was also not significantly different (p = 0.56). This study showed that the safety and efficacy of auto-HCT in elderly patients with multiple myeloma in the era of novel agents compared with younger patients were similar.",
author = "Shohei Mizuno and Koji Kawamura and Ichiro Hanamura and Kazutaka Sunami and Takehiko Mori and Fumihiko Nakamura and Shinsuke Iida and Hideyuki Nakazawa and Masanori Makita and Shinichi Kako and Masashi Sawa and Yasunori Ueda and Hiroyuki Takahashi and Yoshinobu Kanda and Tatsuo Ichinohe and Yoshiko Atsuta and Hiroyuki Takamatsu and Akiyoshi Takami",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41409-019-0478-4",
language = "English",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents

AU - Mizuno, Shohei

AU - Kawamura, Koji

AU - Hanamura, Ichiro

AU - Sunami, Kazutaka

AU - Mori, Takehiko

AU - Nakamura, Fumihiko

AU - Iida, Shinsuke

AU - Nakazawa, Hideyuki

AU - Makita, Masanori

AU - Kako, Shinichi

AU - Sawa, Masashi

AU - Ueda, Yasunori

AU - Takahashi, Hiroyuki

AU - Kanda, Yoshinobu

AU - Ichinohe, Tatsuo

AU - Atsuta, Yoshiko

AU - Takamatsu, Hiroyuki

AU - Takami, Akiyoshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Clinical trials evaluating the role of autologous hematopoietic stem cell transplantation (auto-HCT) in multiple myeloma have mostly included patients aged <65 years. Therefore, this study was aimed to evaluate the efficacy and safety of auto-HCT in elderly patients with multiple myeloma in the era of novel agents. We retrospectively analyzed 2056 patients with multiple myeloma, who underwent auto-HCT in 2007–2014 (287 were aged ≥65 years). We evaluated the 100-day treatment-related mortality (TRM) and overall survival (OS) in two groups; elderly patients (≥65 years) who underwent auto-HCT compared with younger patients (<65 years). In the propensity score–matched-pair analysis used to adjust for possible selection bias, the incidence of 100-day TRM between patients aged <65 (0.4%; 95% confidence interval [CI]: 0.0–2.0%) and ≥65 years (1.2%; 95% CI: 0.3–3.1%) showed no statistically significant difference (p = 0.31). The probability of the 5-year OS after transplantation in those aged <65 (62.5%; 95% CI: 58.6–66.1%) and ≥65 (63.5%; 95% CI: 52.2–72.7%) years was also not significantly different (p = 0.56). This study showed that the safety and efficacy of auto-HCT in elderly patients with multiple myeloma in the era of novel agents compared with younger patients were similar.

AB - Clinical trials evaluating the role of autologous hematopoietic stem cell transplantation (auto-HCT) in multiple myeloma have mostly included patients aged <65 years. Therefore, this study was aimed to evaluate the efficacy and safety of auto-HCT in elderly patients with multiple myeloma in the era of novel agents. We retrospectively analyzed 2056 patients with multiple myeloma, who underwent auto-HCT in 2007–2014 (287 were aged ≥65 years). We evaluated the 100-day treatment-related mortality (TRM) and overall survival (OS) in two groups; elderly patients (≥65 years) who underwent auto-HCT compared with younger patients (<65 years). In the propensity score–matched-pair analysis used to adjust for possible selection bias, the incidence of 100-day TRM between patients aged <65 (0.4%; 95% confidence interval [CI]: 0.0–2.0%) and ≥65 years (1.2%; 95% CI: 0.3–3.1%) showed no statistically significant difference (p = 0.31). The probability of the 5-year OS after transplantation in those aged <65 (62.5%; 95% CI: 58.6–66.1%) and ≥65 (63.5%; 95% CI: 52.2–72.7%) years was also not significantly different (p = 0.56). This study showed that the safety and efficacy of auto-HCT in elderly patients with multiple myeloma in the era of novel agents compared with younger patients were similar.

UR - http://www.scopus.com/inward/record.url?scp=85061941584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061941584&partnerID=8YFLogxK

U2 - 10.1038/s41409-019-0478-4

DO - 10.1038/s41409-019-0478-4

M3 - Article

C2 - 30783208

AN - SCOPUS:85061941584

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -